Placebo-controlled Trial With Nasonex for Nasal Obstruction Secondary to Adenoids Hypertrophy in Children (P04367)(TERMINATED)

Launched by ORGANON AND CO · Nov 5, 2007

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Should be between 2 and 11 years.
• • Should have nasal obstruction for at least 3 months.
• • Should have evidence of adenoids hypertrophy by nasopharyngoscopy, which cause \>50% obstruction of the posterior choanae.
• • May have concomitant allergic rhinitis, by history, \& and specific blood studies; however, the symptoms should be under control during the study period.
• Exclusion Criteria:
• • Patients with less than 50% obstruction of the post choanae.
• • Patients with history of recurrent epistaxis or immunodeficiency.
• • Patients with severe septal deviation.
• • Patients with unilateral or bilateral choanal atresia, large nasal polyps or any nasal mass.
• • Known allergy to the drug.
• • Presence of chronic otitis media defined as: otorreha + perforation (concomitant otitis media with effusion, or recurrent otitis media are not excluded).
• • Cystic fibrosis \& other causes responsible for nasal obstruction.
• • Infection (ie; sinusitis).
• • History of recent surgery or trauma to nose, unless all wounds have healed.